Atossa Therapeutics, Inc.
ATOS
$1.88
$0.116.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.79M | 15.96M | 14.42M | 13.52M | 13.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.60M | 37.14M | 32.86M | 29.99M | 28.06M |
| Operating Income | -39.60M | -37.14M | -32.86M | -29.99M | -28.06M |
| Income Before Tax | -37.64M | -34.77M | -30.18M | -28.72M | -26.34M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -37.64 | -34.77 | -30.18 | -28.72 | -26.34 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.64M | -34.77M | -30.18M | -28.72M | -26.34M |
| EBIT | -39.60M | -37.14M | -32.86M | -29.99M | -28.06M |
| EBITDA | -39.58M | -37.13M | -32.84M | -29.97M | -28.04M |
| EPS Basic | -4.37 | -4.04 | -3.52 | -3.37 | -3.12 |
| Normalized Basic EPS | -2.73 | -2.52 | -2.20 | -1.98 | -1.82 |
| EPS Diluted | -4.37 | -4.04 | -3.52 | -3.37 | -3.12 |
| Normalized Diluted EPS | -2.73 | -2.52 | -2.20 | -1.98 | -1.82 |
| Average Basic Shares Outstanding | 34.46M | 34.46M | 34.29M | 34.06M | 33.83M |
| Average Diluted Shares Outstanding | 34.46M | 34.46M | 34.29M | 34.06M | 33.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |